Scribe Therapeutics priced an upsized initial public offering of 8.58 million shares at USD 15.00 each, the top of its marketed range, raising approximately USD 128.7 million in gross proceeds to advance its in vivo CRISPR gene-editing pipeline for cardiometabolic diseases.
The California-based company sold all shares in the offering, while underwriters received a 30-day option to purchase up to an additional 1.287 million shares. Shares are expected to begin trading on the Nasdaq Global Market on July 24 under the ticker SCTX. Separately, partner Sanofi agreed to purchase 500,000 shares at the IPO price in a concurrent private placement worth approximately USD 7.5 million.
Scribe, co-founded by Nobel laureate Jennifer Doudna, is developing gene-editing therapies designed for direct in vivo delivery. Its lead candidate, STX-1150, uses the company's ELXR epigenetic editing platform to silence the PCSK9 gene and reduce LDL cholesterol without permanently altering the DNA sequence. The program recently entered a Phase I trial in Australia.
The company's earlier-stage pipeline includes STX-1200, which targets LPA to lower lipoprotein(a), and STX-1400, targeting APOC3 for severe hypertriglyceridemia. Both candidates use Scribe's XE CRISPR platform and remain in preclinical development, with Phase I studies planned from 2027 and 2028, respectively.